Last reviewed · How we verify
NCT05529485: PREDICSPILOT
Quantification of Factors Influencing Endothelial Damage During Phacoemulsification
trial testing Cataract surgery by phacoemulsification in Endothelial Cell Loss, Corneal in 121 participants. Completed in 1 August 2022.
1 August 2022
Quick facts
| Lead sponsor | Centre Hospitalier Régional Metz-Thionville |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 12 January 2022 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 August 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Cataract surgery by phacoemulsification
Conditions studied
- Endothelial Cell Loss, Corneal — all drugs for Endothelial Cell Loss, Corneal →
- Cataract — all drugs for Cataract →
- Phacoemulsification — all drugs for Phacoemulsification →
Sponsor
Centre Hospitalier Régional Metz-Thionville
Who can join
18 and older, any sex, with Endothelial Cell Loss, Corneal or Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to determine the principal factors that influence endothelial cell loss three month post cataract surgery. Methods: Multi center observational Cohort study, inclusion period from 12/01/2022 to 10/06/2022. One hundred and seventy-five eyes of hundred and four patients who have appointment for cataract surgical indication were included. The percentage of corneal endothelial cell loss was quantified using specular microscopy before and 3 months after the surgery. 14 variables (pre-operative and intra-operative) that could be associated to endothelial cell injury were selected. A bivariate analysis of relationship between these factors and endothelial cell loss at 3 months was performed by simple linear regression (Wilcoxon and Fischer tests). Multivariate analysis was performed by multiple linear regression in order to identify the factors independently related to endothelial cell loss.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05529485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endothelial Cell Loss, Corneal
Currently open trials in the same condition.
- NCT05587205 — Safety and Tolerability of EO2002 · Phase 1 · recruiting
Other Centre Hospitalier Régional Metz-Thionville trials
Trials by the same sponsor.
- NCT07435389 — VENTILATION DURING SPACEFLIGHT (PHASE 2) · NA · not yet recruiting
- NCT07405996 — Referral of Patients With Biological Abnormalities to an Emergency Department · not yet recruiting
- NCT07406022 — Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. · not yet recruiting
- NCT07515404 — A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study · completed
- NCT07390604 — Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patien · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05529485 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville
- Last refreshed: 10 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing